(19)

(11)

EP 4 096 660 A1

(12)

(43) Date of publication: 07.12.2022 Bulletin 2022/49 (21) Application number: 21703163.2 (22) Date of filing: 26.01.2021

(51) International Patent Classification (IPC):  A61K 31/4439(2006.01) A61K 31/497(2006.01) A61K 31/506(2006.01) A61K 45/06(2006.01) A61K 9/20(2006.01) A61P 13/12(2006.01) A61K 31/404(2006.01) A61K 31/501(2006.01) A61K 31/593(2006.01) A61K 9/00(2006.01) A61K 9/48(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/404; A61K 31/4439; A61K 31/506; A61K 31/497; A61K 31/501; A61K 45/06; A61P 13/12; A61K 31/593; A61K 9/0095; A61K 9/10; A61K 9/107; A61K 9/127; A61K 9/19; A61K 9/2004; A61K 9/4841; A61K 9/4825; A61K 9/1605; A61K 9/2806; A61K 9/0019; A61K 9/08; A61K 9/12; A61K 9/02; A61K 9/0043; A61K 9/0031; A61K 9/006; A61K 9/0073; A61K 9/7023; A61K 47/38; A61K 47/26; A61K 47/20; A61K 47/24   C-Sets: A61K 31/501, A61K 2300/00; A61K 31/593, A61K 2300/00; A61K 31/404, A61K 2300/00; A61K 31/4439, A61K 2300/00; A61K 31/506, A61K 2300/00; A61K 31/497, A61K 2300/00; (86) International application number: PCT/EP2021/051778 (87) International publication number: WO 2021/151905 (05.08.2021 Gazette 2021/31)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 27.01.2020 US 202062966382 P (71) Applicant: EirGen Pharma Ltd. Waterford X91 YV67 (IE)	(72) Inventors: CRUZ, Antonio F. Miami, Florida 33137 (US) FROST, Phillip Miami, Florida 33139 (US) (74) Representative: Pearl Cohen Zedek Latzer Baratz UK LLP  The Gridiron Building One Pancras Square London N1C 4AG London N1C 4AG (GB)